## In the Title:

Please change the title to read:

ANTIBODIES ASSOCIATED WITH ALTERATIONS IN BONE DENSITY

## In the Claims:

Please cancel claims 18, 19, 22 and 88-93 from consideration.

Please add new claims 94-103 to recite as follows:

D1

- 94. (New) An isolated antibody or binding fragment thereof which binds to a TGF-beta binding protein, wherein said binding protein is selected from the group consisting of:
- (a) an isolated polypeptide encoded by a polynucleotide sequence selected from SEQ ID NOs:1, 5, 9, 11, 13, and 15, or complementary sequences thereof;
- (b) an isolated polypeptide selected from SEQ ID NOs: 2, 6, 10, 12, 14, and 16; and
- (c) an isolated polypeptide encoded by a polynucleotide that specifically hybridizes to a polynucleotide encoding the polypeptides of (a) under conditions of high stringency, wherein high stringency conditions are prewashing in 60 mM Tris pH 8.0, 2 mM EDTA, 5x Denhardt's, 6x SSC, 0.1% (w/v) N-laurylsarcosine, 0.5% (w/v) NP-40 (nonidet P-40) overnight at 45°C, followed by two washes with 0.2x SSC containing 0.1% SDS at 45-50°C.
- 95. (New) The isolated antibody or binding fragment thereof of claim 94, wherein the isolated antibody or binding fragment thereof is a polyclonal antibody.
- 96. (New) The isolated antibody or binding fragment thereof of claim 94, wherein the isolated antibody or binding fragment thereof is a monoclonal antibody.
- 97. (New) The isolated antibody or binding fragment thereof of claim 94, wherein the isolated antibody or binding fragment thereof is a humanized antibody.

- 98. (New) The isolated antibody or binding fragment thereof of any one of claims 94-97, wherein the antibody has an affinity of at least 10<sup>-7</sup>M.
- 99. (New) The isolated antibody or binding fragment thereof of any one of claims 94-97, wherein the antibody has an affinity of at least 10<sup>-8</sup>M.
- 100. (New) A hybridoma that produces an antibody according to any one of claims 94-97.
  - 101. (New) A method of producing monoclonal antibodies, comprising:
  - (a) immunizing an animal with a TGF-beta binding protein or portion thereof;
  - (b) harvesting spleen cells from said animal;
  - (c) fusing said spleen cells with a myeloma cell line; and
- (d) culturing said fused cells under conditions that allow the production of said antibody.
- 102. (New) A method for the production of an antibody of any one of claims 94-97 comprising culturing hybridoma cells under conditions that allow the production of said antibody.
- 103. (New) A method for the production of an antibody of any one of claims 94-97 comprising:
  - (a) providing a recombinant host cell capable of producing said antibody; and
- (b) culturing said cell under conditions that allow the production of said antibody.

## **REMARKS**

Applicants submit this Amendment in response to the Office Action mailed November 20, 2001 (Paper No. 5). Claims 18, 19, 22 and 88-93 were pending in the application. Following the above amendments, and as further discussed below in the context of the